The NLRP3 inflammasome is implicated in a host ... in preclinical development but being eyed as a possible treatment for multiple sclerosis.

which has just reported phase 1 results with its first two NLRP3 inhibitors, and ZyVersa Therapeutics with preclinical-stage candidate IC 100 that is being considered for multiple sclerosis.

Our search terms were “NLRP3 inflammasome, multiple sclerosis, experimental autoimmune encephalomyelitis, natural compound, autophagy, small molecular compound, inflammation, mechanism, therapy”. We ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called ...

To build a model that used routine clinical information to screen for anxiety and depression, Patten's group studied 828 MS ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed.

In recently published research in the journal Neurology, the team tracked records for 4,593 people living with multiple sclerosis from 2019 to 2020, 673 in rural areas and 3,920 in urban centers.

Depression and anxiety have been well documented in people with multiple sclerosis (MS), but often are undiagnosed or untreated. A machine learning model may help by analyzing routinely collected ...